Egypt begins vaccine rollout to wider population

accreditation
0:00
play article
Subscribers can listen to this article
  • Egypt will expand its Covid-19 vaccination rollout to elderly people.
  • The country is using vaccines developed by Sinopharm and AstraZeneca.
  • There have been 10 822 deaths so far.


Egypt on Thursday expanded its coronavirus vaccination rollout to include the elderly and people with chronic diseases after several weeks of vaccinating medical staff, the cabinet said.

LIVE | All the latest coronavirus and lockdown updates

Nearly 153 000 people have applied for vaccinations since Sunday when the North African country opened online registration, the cabinet said in a statement.

Egypt, the Arab world's most populous country with more than 100 million, has prepared 40 vaccination centres and plans to increase that number after the arrival of more vaccine batches, Prime Minister Mostafa Madbouly said.

Egypt received 350 000 doses of a coronavirus vaccine developed by China National Pharmaceutical Group (Sinopharm) in two batches since December, in addition to 50 000 doses of a vaccine developed by AstraZeneca in February.

It is hoping to receive vaccines through the Covax facility, a global initiative aimed at providing equitable distribution of vaccines, in the coming weeks.

On 24 February, the Egyptian Drug Authority approved Russia's Sputnik V vaccine for emergency use.

Egypt's Prime Speed Medical Services said it had obtained the right to provide Sputnik V in Egypt in a statement to the stock exchange, without giving details.

Egypt began vaccinating frontline medical staff against Covid-19 on 24 January using the Chinese vaccine.

Those getting the Sinopharm jab have a second dose after 21 days while those who receive the AstraZeneca vaccine wait 12 weeks for the second dose, said Health Minister Hala Zayed.

As of Wednesday, Egypt had confirmed 184 168 coronavirus cases, including 10 822 deaths, since the start of the pandemic.

However, health officials say the real number is likely far higher due to a relatively low rate of coronavirus testing and the exclusion of private test results.


Do you want to know more about this topic? Sign up for one of News24's 33 newsletters to receive the information you want in your inbox. Special newsletters are available to subscribers.

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Rand - Dollar
15.84
+0.2%
Rand - Pound
19.79
+0.0%
Rand - Euro
16.72
+0.4%
Rand - Aus dollar
11.16
+0.2%
Rand - Yen
0.12
+0.3%
Gold
1,845.51
+0.2%
Silver
21.76
-0.7%
Palladium
1,968.00
-2.0%
Platinum
957.50
-1.0%
Brent Crude
112.04
+2.6%
Top 40
61,000
-1.2%
All Share
67,575
-1.0%
Resource 10
72,529
+1.6%
Industrial 25
72,948
-3.9%
Financial 15
15,746
+0.1%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE